Leerink Partnrs Has Bullish Outlook for NAMS FY2024 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a report issued on Wednesday, November 6th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings per share of ($1.77) for the year, up from their previous estimate of ($2.02). The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma's Q4 2024 earnings at ($0.46) EPS, FY2025 earnings at ($1.50) EPS, FY2026 earnings at ($1.40) EPS and FY2027 earnings at ($1.45) EPS.

A number of other equities analysts also recently issued reports on the company. Needham & Company LLC restated a "buy" rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday. Royal Bank of Canada reaffirmed an "outperform" rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Piper Sandler reiterated an "overweight" rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $33.80.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS traded up $0.47 during trading hours on Monday, hitting $24.59. The company's stock had a trading volume of 538,680 shares, compared to its average volume of 262,282. The company's 50 day simple moving average is $17.67 and its two-hundred day simple moving average is $18.48. NewAmsterdam Pharma has a 12 month low of $8.64 and a 12 month high of $26.35.

Insider Buying and Selling

In other news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NAMS. Banque Cantonale Vaudoise purchased a new position in NewAmsterdam Pharma during the second quarter valued at approximately $38,000. Sei Investments Co. grew its holdings in NewAmsterdam Pharma by 49.1% in the second quarter. Sei Investments Co. now owns 24,561 shares of the company's stock worth $472,000 after purchasing an additional 8,087 shares during the last quarter. Wolverine Asset Management LLC lifted its holdings in shares of NewAmsterdam Pharma by 117.7% during the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company's stock valued at $298,000 after purchasing an additional 8,394 shares during the last quarter. TimesSquare Capital Management LLC grew its stake in NewAmsterdam Pharma by 3.7% during the 3rd quarter. TimesSquare Capital Management LLC now owns 255,245 shares of the company's stock worth $4,237,000 after buying an additional 9,160 shares during the last quarter. Finally, Rosalind Advisors Inc. purchased a new stake in NewAmsterdam Pharma in the second quarter valued at about $194,000. Institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.